MedPath

ABP-450

Generic Name
ABP-450
Clinical Trials
Related News

DWP450 for Treating Moderate to Severe Glabellar Lines

Phase 3
Completed
Conditions
Moderate to Severe Glabellar Lines
Interventions
First Posted Date
2024-04-09
Last Posted Date
2024-04-09
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Target Recruit Count
473
Registration Number
NCT06354127
Locations
🇨🇳

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China

Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines

Recruiting
Conditions
Glabellar Frown Lines
Interventions
First Posted Date
2022-08-01
Last Posted Date
2024-05-24
Lead Sponsor
Evolus, Inc.
Target Recruit Count
750
Registration Number
NCT05481931
Locations
🇩🇪

Cologne Dermatology, Cologne, Germany

Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD

Early Phase 1
Completed
Conditions
Glabellar Frown Lines
Interventions
First Posted Date
2021-11-22
Last Posted Date
2024-02-06
Lead Sponsor
Clinical Testing of Beverly Hills
Target Recruit Count
30
Registration Number
NCT05129319
Locations
🇺🇸

Clinical Testing of Beverly Hills, Encino, California, United States

Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention

Phase 2
Conditions
Migraine
Interventions
First Posted Date
2021-08-23
Last Posted Date
2024-08-14
Lead Sponsor
AEON Biopharma, Inc.
Target Recruit Count
666
Registration Number
NCT05016661
Locations
🇺🇸

Quest Research Institute - Hunt - PPDS, Farmington Hills, Michigan, United States

🇺🇸

NeuroTrials Research Inc. - Clinedge - PPDS, Atlanta, Georgia, United States

🇺🇸

Kansas Institute of Research, LLC, Overland Park, Kansas, United States

and more 52 locations

Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia

Phase 2
Completed
Conditions
Cervical Dystonia
Interventions
First Posted Date
2021-05-04
Last Posted Date
2024-08-22
Lead Sponsor
AEON Biopharma, Inc.
Target Recruit Count
51
Registration Number
NCT04871451
Locations
🇺🇸

University of New Mexico, Albuquerque, New Mexico, United States

🇺🇸

New England Institute for Neurology and Headache, Stamford, Connecticut, United States

🇺🇸

Neuro Pain Medical Center, Fresno, California, United States

and more 17 locations

A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia

Phase 2
Completed
Conditions
Cervical Dystonia
Interventions
Drug: Placebo
First Posted Date
2021-04-20
Last Posted Date
2024-02-14
Lead Sponsor
AEON Biopharma, Inc.
Target Recruit Count
61
Registration Number
NCT04849988
Locations
🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

Neuro Pain Medical Center, Fresno, California, United States

🇺🇸

Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States

and more 18 locations

Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

Early Phase 1
Active, not recruiting
Conditions
Glabellar Frown Lines
Interventions
Drug: Onabotulinum toxin A
First Posted Date
2021-01-20
Last Posted Date
2023-12-14
Lead Sponsor
University of Southern California
Target Recruit Count
20
Registration Number
NCT04715048
Locations
🇺🇸

USC Roski Eye Institute, Los Angeles, California, United States

Efficacy and Safety of DWP450 in Subjects With Benign Masseteric Hypertrophy

Phase 3
Completed
Conditions
Benign Masseteric Hypertrophy
Interventions
Drug: Placebo
First Posted Date
2020-03-04
Last Posted Date
2022-11-30
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Target Recruit Count
180
Registration Number
NCT04294251
Locations
🇰🇷

Chung-ang University Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy